/
Metabolic & Endocrine
Type 2 Diabetes Mellitus
76
Pipeline Programs↗
95
Active Trials↗
107
Companies Involved↗
Type 2 Diabetes Mellitus is a moderately active landscape with 76 programs across 107 companies. The most active players are Gan & Lee Pharmaceuticals., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Haisco Pharmaceutical Group Co., Ltd.. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical53
Phase 27
Phase 314
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
67 of 70 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 70 classified programs, each share of the total. Modality classified for 97% of 76 pipeline programs.
Analysis
Trial Status
1,048
clinical trials
Completed774 · 74%
Terminated83 · 8%
Unknown status75 · 7%
Not yet recruiting39 · 4%
Recruiting34 · 3%
Withdrawn21 · 2%
Other22 · 2%
Clinical Trials
Trial Activity
1048 trials
Page 1 of 70
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)